C. Michael Gibson, MS, MD, MSCAI
C. Michael Gibson, MS, MD, MSCAI pioneered our understanding of the open artery and the open microvasculature hypothesis in the setting of heart attack. As an innovator, Gibson invented measures of coronary blood flow that are widely used today (the TIMI frame count (cited 2,131 times) and the TIMI myocardial perfusion grade (cited 1,089 times).
Gibson is an interventional cardiologist, cardiovascular researcher & educator. He is the CEO of the combined non-profit Baim and PERFUSE research institutes at Harvard Medical School.
The institutes have led over 1,000 studies, published 5,500 manuscripts in the peer-reviewed literature (including 144 in the New England Journal), and led 100 FDA submissions from their network of 7,000 sites worldwide. Since 2014, Thomson Reuters has consistently ranked him as one of the world's most highly cited authors in all of science. In 2021, he was named one of the Fifty of the Most Influential Voices in Healthcare by Medika Life. His work has been cited over 148,000 times, and he has an H index of 134 and an i10-index of 549.
May 2 - 4, 2024
Long Beach, California